NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -115.64% | 8.40% | 13.89% | 17.67% | 4.86% |
| Total Depreciation and Amortization | -29.41% | -14.00% | 1.53% | 94.27% | -48.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 118.26% | -8.10% | -18.35% | 618.49% | -79.98% |
| Change in Net Operating Assets | -69.54% | 347.94% | 112.62% | -220.81% | 287.07% |
| Cash from Operations | -133.26% | 703.26% | 94.55% | -116.88% | 24.62% |
| Capital Expenditure | 16.30% | 6.67% | 2.87% | -72.76% | 5.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -163.56% | 105.75% | -240.70% | 144.97% | 329.69% |
| Cash from Investing | -317.90% | 102.72% | -252.08% | 149.97% | 470.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,585.00% | -96.98% | 1,453.05% | -88.85% | 63.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,585.00% | -99.89% | 40,893.90% | -88.85% | 63.11% |
| Foreign Exchange rate Adjustments | -247.13% | 212.99% | -37.50% | -128.00% | 306.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.32% | 107.18% | -234.51% | 149.62% | 8,862.93% |